In what is a major development for the industry, Switzerland-based pharmaceutical giant Roche has announced a $50 billion investment plan in the US. Indeed, the company is set to increase its presence in the country to avoid the ongoing threat of tariffs on the sector.
The investment should be massive for the economy, creating more than 12,000 jobs, according to a press release. Moreover, the move comes after US President Trump said that he would no longer exempt the industry from facing import duties. That decision has many companies in the sector looking for much-needed protections.
JUST IN: Swiss pharmaceutical giant Roche to invest $50 billion in the United States to avoid tariffs.
— Watcher.Guru (@WatcherGuru) April 23, 2025
Also Read: Trump: “Tariffs are Going Well, Everybody Wants to Negotiate”
Roche Announces Major US Investment as Pharmaceutical Firm Eyes Tariff Protection
For much of April, the global economy has sought ways to deal with the United States’ new Liberation Day tariff plan. It announced the move to start the month, with nations facing increased import duties. The purpose of the policy is to balance trade, although tensions have escalated with countries like China threatening a trade war.
However, the policy has driven increased interest and participation in the United States economy. The latest firm to embrace those efforts is Roche, with the Swiss pharmaceutical company announcing a new $50 billion US investment plan. Indeed, it strengthened the company’s already strong presence in the country.
Also Read: Janet Yellen Names the Person Who Is Eroding Trust in the US, Dollar
The investments will be made over the next five years, they said. Moreover, it will build on its already 25,000 jobs in the United States. Moreover, it will inject capital to create new research and development sites in Indiana, Pennsylvania, Massachusetts, and California.
US President Trump had previously warned that a tariff on pharmaceuticals was on the way. The industry had long been exempt from such import tax increases. Yet, that was poised to change this month, according to the president.
Conversely, Roche isn’t alone, as Swiss-based Novartis announced a similar $23 billion investment plan in the country. Indeed, they project to create more than 4,000 jobs. There is reason to believe that it could be the start of a new trend for international businesses.
